Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carrie Lucas

Nurse Practitioner Mexico, MO Nurse Practitioner

NPI 1770504219 CMS profile 11067245

515 E Promenade St, Mexico, MO 65265

Open in the dashboard

General payments

$1,810

103 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie Lucas of Mexico, MO is reported in the CMS Open Payments database as having received $1,810 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $252 12
2024 General $300 15
2023 General $392 24
2022 General $294 20
2021 General $573 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Lucas
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Carrie Lucas were reported at $252. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Carrie Lucas Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $573 $135 $40–$426 $132
2022 $294 $152 $48–$470 $149
2023 $392 $166 $54–$529 $160
2024 $300 $173 $55–$556 $164
2025 $252 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,469 89 payments
  2. Esperion Therapeutics, Inc. $88 1 payment
  3. Pfizer Inc. $83 4 payments
  4. Vertex Pharmaceuticals Incorporated $73 3 payments
  5. AstraZeneca Pharmaceuticals LP $44 3 payments
  6. Boston Scientific Corporation $39 2 payments
  7. Vertos Medical, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,810 103 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $432 26 payments
  2. Proclaim IPG $371 25 payments
  3. OCTRODE $156 10 payments
  4. PROCLAIM Neuromodulation $90 5 payments
  5. NEXLETOL $88 1 payment
  6. NEXLIZET $88 1 payment
  7. ELIQUIS $83 4 payments
  8. PROCLAIM Neuromodulation $83 5 payments
  9. JOURNAVX $73 3 payments
  10. PROCLAIM Structural Heart $66 3 payments
  11. Other $368 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

2,761

Median for Nurse Practitioner: 389

Drug cost

$30,863

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 953 $11,573
Baclofen Generic 612 $6,264
Duloxetine Hcl Generic 476 $5,060
Methocarbamol Generic 263 $2,752
Celecoxib Generic 49 $1,724
Tizanidine Hcl Generic 151 $1,333
Chlorzoxazone Generic 14 $577
Nortriptyline Hcl Generic 70 $487
Meloxicam Generic 99 $436
Diclofenac Sodium Generic 36 $420

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$63,038

Of which drugs: $2,726

Medicare patients

498

Average age 77

Services billed

1,931

303 women, 195 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 32%
Osteoporosis 24%
Depression 22%
Chronic kidney disease 21%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 720 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record